P

Inventor

ZHANG FENGLEI

US31 patents
⚠️ This page may combine multiple inventors who share the name “ZHANG FENGLEI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

INCYTE CORP

30 patents
US10450313B2Oct 22, 2019

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP32 citations98
US10040790B2Aug 7, 2018

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP36 citations98
US9533984B2Jan 3, 2017

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP42 citations98
US11407749B2Aug 9, 2022

Heterocyclic compounds as immunomodulators

INCYTE CORP23 citations94
US11339149B2May 24, 2022

Heterocyclic compounds as immunomodulators

INCYTE CORP24 citations94
US10947230B2Mar 16, 2021

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP26 citations94
US10800768B2Oct 13, 2020

Heterocyclic compounds as immunomodulators

INCYTE CORP30 citations94
US10174030B2Jan 8, 2019

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP14 citations94
US9944647B2Apr 17, 2018

Heterocyclic compounds as LSD1 inhibitors

INCYTE CORP30 citations94
US9670210B2Jun 6, 2017

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP23 citations94
US9493442B2Nov 15, 2016

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP30 citations94
US7723349B2May 25, 2010

Aza spiro alkane derivatives as inhibitors of metalloproteases

INCYTE CORP21 citations93
US11613536B2Mar 28, 2023

Heterocyclic compounds as immunomodulators

INCYTE CORP15 citations86
US11530214B2Dec 20, 2022

Bicyclic heterocycles as FGFR inhibitors

INCYTE CORP7 citations86
US11465981B2Oct 11, 2022

Heterocyclic compounds as immunomodulators

INCYTE CORP18 citations86
US10300051B2May 28, 2019

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP14 citations86
US10800779B2Oct 13, 2020

Heterocyclic compounds as LSD1 inhibitors

INCYTE CORP6 citations84
US10717737B2Jul 21, 2020

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP7 citations84
US9801877B2Oct 31, 2017

AZA spiro alkane derivatives as inhibitors of metalloproteases

INCYTE CORP7 citations84
US11673894B2Jun 13, 2023

Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

INCYTE CORP4 citations74
US8039471B2Oct 18, 2011

Aza spiro alkane derivatives as inhibitors of metalloproteases

INCYTE CORP5 citations74
US11247992B2Feb 15, 2022

Cyclopropylamines as LSD1 inhibitors

INCYTE CORP3 citations73
US9403775B2Aug 2, 2016

AZA spiro alkane derivatives as inhibitors of metalloproteases

INCYTE CORP3 citations73
US11472791B2Oct 18, 2022

Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

INCYTE CORP7 citations72
US11229631B2Jan 25, 2022

Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors

INCYTE CORP0 citations63
US11873309B2Jan 16, 2024

Heterocyclic compounds as immunomodulators

INCYTE CORP1 citations62
US11401272B2Aug 2, 2022

Heterocyclic compounds as LSD1 inhibitors

INCYTE CORP0 citations62
US12378243B2Aug 5, 2025

Quinoline compounds as inhibitors of KRAS

INCYTE CORP0 citations56
US12516044B2Jan 6, 2026

Heterocyclic compounds as immunomodulators

INCYTE CORP0 citations52
US10226459B2Mar 12, 2019

Aza spiro alkane derivatives as inhibitors of metalloproteases

INCYTE CORP0 citations52

YAO WENQING

1 patent